Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to secure a Biologics License Application (BLA) for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until September 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Group 1 - The Rosen Law Firm is reminding investors who purchased 3D Systems Corporation securities between August 13, 2024, and May 12, 2025, of the August 12, 2025, lead plaintiff deadline for a class action lawsuit [1][2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [2][5] Group 2 - The lawsuit alleges that during the class period, 3D Systems made false and misleading statements regarding its business resilience and the impact of weakened customer spending [4] - It is claimed that the updated milestone criteria in a partnership with United Therapeutics Corporation would negatively affect 3D Systems' Regenerative Medicine Program revenue [4] - The lawsuit asserts that these misleading public statements resulted in investor damages when the true information became public [4] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on July 21, 2025 [1] Group 1: Class Action Details - Investors who purchased DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3] - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4] Group 2: Allegations Against DoubleVerify - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5] - It is claimed that DoubleVerify's high-margin Activation Services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5] - The lawsuit also states that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and its risk disclosures were materially misleading [5]

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged misleading statements regarding its drug candidates, potentially impacting investors who purchased securities during the specified period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to purchasers of Biohaven securities between March 24, 2023, and May 14, 2025 [1]. - Allegations include overstated regulatory prospects for the drug troriluzole and its efficacy for treating spinocerebellar ataxia and bipolar disorder, which may have negatively affected Biohaven's business and financial condition [5]. Group 2: Investor Information - Investors who purchased Biohaven securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Viewpoint - A securities class action lawsuit has been filed against XPLR Infrastructure, LP, alleging misleading statements and omissions regarding the company's financial condition and business model during the class period from September 27, 2023, to January 27, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed by Scott+Scott Attorneys at Law LLP in the U.S. District Court for the Southern District of California [1]. - The class action asserts claims under the Securities Exchange Act of 1934 and SEC Rule 10b-5 on behalf of all individuals who purchased XPLR common units during the specified class period [1]. - The case is titled James Alvrus v. XPLR Infrastructure, LP, et al., Case No. 3:25-cv-01755 [1]. Group 2: Allegations Against XPLR - Defendants allegedly made misleading statements about XPLR's operations as a yieldco, failing to disclose struggles in maintaining operations [3]. - The lawsuit claims that XPLR entered into financing arrangements to temporarily alleviate operational issues while downplaying associated risks [3]. - It is alleged that XPLR could not resolve these financings before maturity without risking significant unitholder dilution, leading to a planned halt in cash distributions to investors [3]. - The lawsuit contends that the yieldco business model and distribution growth rate were unsustainable, rendering the defendants' public statements materially false and misleading [3]. Group 3: Market Reaction - On January 28, 2025, XPLR announced a suspension of cash distributions to common unitholders and a shift away from its yieldco model, which shocked investors [4]. - Following this announcement, XPLR's common unit price fell from $15.80 on January 27, 2025, to $10.49 on January 29, 2025, marking a decline of $5.31 per unit, or nearly 35% [4].

Core Viewpoint - Monteverde & Associates PC is investigating Royal Gold, Inc. regarding its merger with Sandstorm Gold Ltd, questioning the fairness of the deal where existing Royal Gold shareholders will own approximately 77% of the combined company [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is headquartered in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Merger Details - The proposed merger between Royal Gold, Inc. and Sandstorm Gold Ltd will result in existing Royal Gold shareholders owning about 77% of the new entity [1].

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline. SO WHAT: If you purchased DoubleVerify common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of 3D Systems Corporation (NYSE: DDD) between August 13, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important August 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased 3D Systems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. - Investors who purchased Elevance common stock between April 18, 2024, and October 16, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4]. - The deadline to move the Court to serve as lead plaintiff is July 11, 2025, and a lead plaintiff acts on behalf of other class members in directing the litigation [2]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health misrepresented its monitoring of cost trends associated with the Medicaid redetermination process, leading investors to believe that premium rates were sufficient to address the risk profiles of Medicaid patients [4]. - It is alleged that the company failed to disclose that the acuity and utilization of its Medicaid members were rising significantly, as healthier members were being removed from Medicaid programs [4]. - The misrepresentation of financial guidance and rate negotiations with states is said to have caused investor damages when the true situation was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - Compass Diversified (NYSE: CODI) has warned investors not to rely on its previously issued financial statements for fiscal years ending December 31, 2022 and 2023 due to expanded accounting irregularities [1][5]. Group 1: Financial Irregularities - The company disclosed that accounting irregularities at its subsidiary, Lugano Holding, affected financial statements for fiscal years 2022, 2023, and 2024, necessitating restatements [4][5]. - The irregularities include violations of applicable accounting rules and industry practices concerning financing, accounting, and inventory procedures [9]. Group 2: Legal Actions - Following the announcement of accounting issues, Compass Diversified is facing multiple class-action lawsuits, with the lead plaintiff's deadline set for July 8, 2025 [3][4]. - The amended complaint in the case Moreno v. Compass Group Diversified Holdings LLC seeks to represent investors who purchased shares from February 24, 2022, to May 7, 2025 [3][4]. Group 3: Market Reaction - The market reacted severely to the news, with Compass Diversified's stock price dropping by over 62% following the disclosure of the accounting irregularities [7]. Group 4: Investigations - Hagens Berman, a national investor rights law firm, is conducting an investigation into potential securities violations by Compass Diversified [8][10]. - The firm's investigation highlights a lack of effective internal controls over financial reporting, leading to materially misstated financial results [9].